NEW YORK, NY / ACCESSWIRE / May 16, 2017 / Despite losses for both Aurinia and Bellerophon in the first quarter, the companies had some encouraging news about products they are developing. This couldn't however save shares from entering into red territory on Monday.

RDI Initiates Coverage on:

Aurinia Pharmaceuticals Inc.
https://ub.rdinvesting.com/news/?ticker=AUPH

Bellerophon Therapeutics LLC
https://ub.rdinvesting.com/news/?ticker=BLPH

Aurinia Pharmaceuticals Inc.'s shares closed down 5.73% yesterday after reporting a $51.9 million loss in the company's first quarter report. The Canada-based company had a loss of 92 cents on a per-share basis. The only plus was that the company had some positive news about voclosporin, an experimental immunosuppressant drug it's been developing. CEO Richard Glickman commented, "I am proud of the important clinical, regulatory and financial milestones our team has successfully achieved in our first quarter this year. We released positive 48-week results from our Phase IIb AURA-LV ("AURA") trial of voclosporin, which demonstrated significantly improved complete remission rates in patients suffering from lupus nephritis."

"We also believe we have a clear path forward with regulators to develop voclosporin in major markets and have successfully funded the Company's initiated Phase III lupus nephritis clinical trial ("AURORA") and operations through 2020. Furthermore, based on the results of our AURA trial and regulatory feedback, we have moved diligently into our AURORA trial with several sites initiated and currently screening patients. Our clinical team is focused on continuing to initiate sites with an aggressive patient recruitment program. The AURORA trial design is consistent with that of the recently completed AURA clinical trial. We believe that the totality of data from both the AURORA and AURA trials will ultimately serve as the basis for a New Drug Application ("NDA") submission as well as regulatory submissions in other major global markets." Shares of Aurinia have more than tripled in the last twelve months.

Access RDI's Aurinia Pharmaceuticals Research Report at:
https://ub.rdinvesting.com/news/?ticker=AUPH

Bellerophon Therapeutics LLC's shares closed down 5.10% on Monday after the clinical-stage biotherapeutics company posted a first quarter loss in its earnings report. For the first quarter ended March 31, 2017, Bellerophon reported a loss of $19.1 million. On a per share basis, the company had a loss of 60 cents. The company did have some encouraging news about its INOpulse® delivery system in pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF).

Fabian Tenenbaum, Chief Executive Officer of Bellerophon Therapeutics stated, "There are currently no therapies to treat pulmonary hypertension in IPF and we believe that inhaled nitric oxide delivered by means of the INOpulse® delivery system is uniquely positioned to provide targeted delivery without the systemic concerns of other therapies. In addition, we expect to communicate the results of our Phase 2 trials for INOpulse therapy to treat pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) around mid 2017."

Access RDI's Bellerophon Therapeutics Research Report at:
https://ub.rdinvesting.com/news/?ticker=BLPH

Our Actionable Research on Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) and Bellerophon Therapeutics LLC (NASDAQ: BLPH) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com